Selwyn Ho, MB BS

Selwyn Ho, MB BS

Position: Chief Business Officer

Dr. Selwyn Ho has served as an advisor to the company since January 2020 and since January 2021 as our Chief Business Officer. He has over 20 years of consulting and biopharmaceutical experience through his own consulting firm, and in senior positions in multiple pharmaceutical organisations, leading Global, Regional and Country teams responsible for product development, product strategy, medical affairs and commercialization, resulting in the successful launches of medicines in the inflammation and immunology, ophthalmology and cardiology therapeutic areas. Most recently, he was Vice President, Head of Market Access and Vice President, Head of Strategic Marketing, at Dermira Inc., a specialty Dermatology company that was acquired by Eli Lilly in 2020. Prior to Dermira, Dr. Ho held several senior strategic and operational leadership positions at UCB S.A. in immunology (Rheumatology, Gastroenterology and Dermatology), and at Allergan, as U.K. Managing Director & Country Manager, and Head of EAME Retina Franchise. He received his medical degree (MB BS) and B.Sc. in Pharmacology from Imperial College, University of London and practiced medicine in Anaesthesiology and Intensive Care.